These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33535253)

  • 1. In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of 3-methyl-3,4-dihydroquinazolin-2(1H)-one Derivatives.
    Jesumoroti OJ; Beteck RM; Legoabe LJ
    Drug Res (Stuttg); 2021 Jul; 71(6):335-340. PubMed ID: 33535253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
    Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.
    Jones AJ; Kaiser M; Avery VM
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1859-61. PubMed ID: 26666915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 4-[4-(4-methylpiperazin-1-yl)phenyl]-6-arylpyrimidine derivatives and their antitrypanosomal activities against T.brucei.
    Taylor AE; Hering M; Elsegood MRJ; Teat SJ; Weaver GW; Arroo RRJ; Kaiser M; Maeser P; Bhambra AS
    Bioorg Med Chem Lett; 2024 Sep; 109():129825. PubMed ID: 38823730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.
    Pham T; Walden M; Butler C; Diaz-Gonzalez R; Pérez-Moreno G; Ceballos-Pérez G; Gomez-Pérez V; García-Hernández R; Zecca H; Krakoff E; Kopec B; Ichire O; Mackenzie C; Pitot M; Ruiz LM; Gamarro F; González-Pacanowska D; Navarro M; Dounay AB
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3629-3635. PubMed ID: 28729055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
    Hiltensperger G; Jones NG; Niedermeier S; Stich A; Kaiser M; Jung J; Puhl S; Damme A; Braunschweig H; Meinel L; Engstler M; Holzgrabe U
    J Med Chem; 2012 Mar; 55(6):2538-48. PubMed ID: 22376072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
    Kaiser M; Bray MA; Cal M; Bourdin Trunz B; Torreele E; Brun R
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5602-8. PubMed ID: 21911566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines.
    Robinson WJ; Taylor AE; Lauga-Cami S; Weaver GW; Arroo RRJ; Kaiser M; Gul S; Kuzikov M; Ellinger B; Singh K; Schirmeister T; Botana A; Eurtivong C; Bhambra AS
    Eur J Med Chem; 2021 Jan; 209():112871. PubMed ID: 33070078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma brucei.
    Zimmermann S; Kaiser M; Brun R; Hamburger M; Adams M
    Planta Med; 2012 Apr; 78(6):553-6. PubMed ID: 22331812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of an orally active nitrothiophene-based antitrypanosomal agent.
    Ajayi O; Metibemu DS; Crown O; Adeyinka OS; Kaiser M; Shoji N; Silva M; Rodriguez A; Ogungbe IV
    Eur J Med Chem; 2024 Jan; 263():115954. PubMed ID: 37984297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.
    Martínez-García M; Bart JM; Campos-Salinas J; Valdivia E; Martínez-Bueno M; González-Rey E; Navarro M; Maqueda M; Cebrián R; Pérez-Victoria JM
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):203-212. PubMed ID: 29649664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro anti-trypanosomal activity of synthetic nitrofurantoin-triazole hybrids against Trypanosoma species causing human African trypanosomosis.
    Seetsi A; N'da DD; Molefe-Nyembe N; Suganuma K; Ramatla T; Thekisoe O
    Fundam Clin Pharmacol; 2024 Feb; 38(1):72-83. PubMed ID: 37479675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
    Wenzler T; Boykin DW; Ismail MA; Hall JE; Tidwell RR; Brun R
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4185-92. PubMed ID: 19620327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug transport and drug resistance in African trypanosomes.
    Mäser P; Lüscher A; Kaminsky R
    Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of the antitrypanosomal activity of fractions of Holarrhena africana.
    Nwodo NJ; Brun R; Osadebe PO
    J Ethnopharmacol; 2007 Sep; 113(3):556-9. PubMed ID: 17728085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro Anti-Trypanosomal Activities of Indanone-Based Chalcones.
    Beteck RM; Legoabe LJ; Isaacs M; Hoppe HC
    Drug Res (Stuttg); 2019 Jun; 69(6):337-341. PubMed ID: 30452077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The story of CGP 40 215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense.
    Brun R; Burri C; Gichuki CW
    Trop Med Int Health; 2001 May; 6(5):362-8. PubMed ID: 11348531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis.
    Vodnala SK; Lundbäck T; Sjöberg B; Svensson R; Rottenberg ME; Hammarström LG
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1012-8. PubMed ID: 23254423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship study of sesquiterpene lactones and their semi-synthetic amino derivatives as potential antitrypanosomal products.
    Zimmermann S; Fouché G; De Mieri M; Yoshimoto Y; Usuki T; Nthambeleni R; Parkinson CJ; van der Westhuyzen C; Kaiser M; Hamburger M; Adams M
    Molecules; 2014 Mar; 19(3):3523-38. PubMed ID: 24662071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitrypanosomal Chloronitrobenzamides.
    Carrillo AK; Kadayat TM; Hwang JY; Chen Y; Zhu F; Holbrook G; Gillingwater K; Connelly MC; Yang L; Kaiser M; Guy RK
    J Med Chem; 2024 Mar; 67(5):3437-3447. PubMed ID: 38363074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.